Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application.
The purpose of this study was to examine the therapeutic potential of ranolazine, a novel antianginal drug, as an adjunctive therapy to hyperkalemic cardioplegia. Rat hearts were Langendorff-perfused and exposed to 40 minutes of ischemia and 30 minutes of reperfusion without (control) or with cardioplegia or cardioplegia with 50 micromol/L ranolazine. During ischemia, cardioplegia prolonged time to contracture, defined as the time to reach an intraventricular pressure of 20 mm Hg, from 12 +/- 1 minute (control) to 25 +/- 2 minutes (P < .05). Ranolazine supplement further lengthened the time to contracture to 34 +/- 2 minutes (P < .05). Ischemia/reperfusion caused a dramatic elevation in left ventricular end diastolic pressure (LVEDP) during reperfusion. Cardioplegia lessened the LVEDP elevation measured at 30 minutes of reperfusion from 76 +/- 3 mm Hg (control) to 32 +/- 3 mm Hg (P < .05). The increase in LVEDP was reduced even further to 17 +/- 2 mm Hg in hearts receiving cardioplegia plus ranolazine (P < .05). These results suggest that addition of ranolazine during hyperkalemic ischemic cardioplegic arrest is beneficial and provides further protection against contracture.
Hwang
Hyosook
H
Heart Institute, Good Samaritan Hospital, Los Angeles, California 90017, USA.
Arcidi
Joseph M
JM
Hale
Sharon L
SL
Simkhovich
Boris Z
BZ
Belardinelli
Luiz
L
Dhalla
Arvinder K
AK
Shryock
John C
JC
Kloner
Robert A
RA